A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

Maio, Michele; Lahn, Michael; Giacomo, Anna Maria Di; Covre, Alessia; Calabrò, Luana; Ibrahim, Ramy; Fox, Bernard A.

doi:10.1186/s13046-021-02023-4

Cited by 3 publications

(1 citation statement)

References 124 publications

(161 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential interplay between COVID-19 infection and treatment with immune-checkpoint inhibitors of patients with a melanoma is still unknown. Nevertheless, preliminary evidence and case reports suggest that anti-PD1 therapy does not worsen the course of COVID-19, allowing patients with cancer to continue their treatment [ 29 ]. In this Italian multicenter study by Pala et al, out of 169 patients with unresectable stage III or IV melanomas treated with immunotherapy, 104 continued without modifications, and among 15 patients showing symptoms compatible with COVID-19, only one tested positive on the nasopharyngeal swab [ 30 ].…”

Section: Advanced Melanoma Management and Immunotherapy In The Covid-19 Eramentioning

confidence: 99%

Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience

Cariti

Merli

Avallone

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: The current COVID-19 pandemic has influenced the modus operandi of all fields of medicine, significantly impacting patients with oncological diseases and multiple comorbidities. Thus, in recent months, the establishment of melanoma management during the emergency has become a major area of interest. In addition to original articles, case reports and specific guidelines for the period have been developed. Purpose: This article aims to evaluate whether melanoma management has been changed by the outbreak of COVID-19, and if so, what the consequences are. We summarized the main issues concerning the screening of suspicious lesions, the diagnosis of primary melanoma, and the management of early-stage and advanced melanomas during the pandemic. Additionally, we report on the experience of our dermatological clinic in northern Italy. Methods: We performed a literature review evaluating articles on melanomas and COVID-19 published in the last two years on PubMed, as well as considering publications by major healthcare organizations. Concerning oncological practice in our center, we collected data on surgical and therapeutic procedures in patients with a melanoma performed during the first months of the pandemic. Conclusions: During the emergency period, the evaluation of suspicious skin lesions was ensured as much as possible. However, the reduced level of access to medical care led to a documented delay in the diagnosis of new melanomas. When detected, the management of early-stage and advanced melanomas was fully guaranteed, whereas the follow-up visits of disease-free patients have been postponed or replaced with a teleconsultation when possible.

show abstract

Section: Advanced Melanoma Management and Immunotherapy In The Covid-19 Eramentioning

confidence: 99%